In a report released today, Peter Lawson from Barclays maintained a Buy rating on Tango Therapeutics (TNGX – Research Report), with a price target of $18.00. The company’s shares closed yesterday at $7.91.
According to TipRanks, Lawson is a 4-star analyst with an average return of 7.9% and a 44.92% success rate. Lawson covers the Healthcare sector, focusing on stocks such as Blueprint Medicines, Syndax Pharmaceuticals, and Immunocore Holdings.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Tango Therapeutics with a $18.25 average price target.
Based on Tango Therapeutics’ latest earnings release for the quarter ending December 31, the company reported a quarterly revenue of $5.43 million and a GAAP net loss of $30.76 million. In comparison, last year the company earned a revenue of $6.41 million and had a GAAP net loss of $29.06 million
Based on the recent corporate insider activity of 21 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of TNGX in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Tango Therapeutics (TNGX) Company Description:
BCTG Acquisition Corp is a blank check company.
Read More on TNGX:
- Cantor starts Tango Therapeutics with Overweight on tumor pipeline
- Tango Therapeutics initiated with an Overweight at Cantor Fitzgerald
- Tango Therapeutics price target raised to $17 from $16 at H.C. Wainwright
- Navigating the AI Minefield: Tango Therapeutics’ Struggle with Security Risks and EU Regulations
- Tango Therapeutics reports Q4 EPS (32c), consensus (28c)
